1. "Melanoma and Immunotherapeutics Service"
Formats
  1. Journal Article (954)
  2. Meeting Abstract (771)
  3. Book Section (42)
  4. Editorial (32)
  5. Review (26)
  6. Research Letter (15)
  7. Guidelines (6)
  8. Correspondence (5)
  9. Conference Paper (4)
  10. Miscellaneous (3)
  11. Book Whole (2)
Groups
  1. Department of Medicine (1860)
  2. Melanoma and Immunotherapeutics Service (1860)
  3. Solid Tumor Oncology Division (1860)
  4. GSK Faculty (1050)
  5. Melanoma Disease Management Team (782)
  6. Hematologic Malignancies, Division of (507)

More Groups

People
  1. Jedd Wolchok (905)
  2. Taha Merghoub (364)
  3. Michael Postow (361)
  4. Paul Chapman (326)
  5. Alexander Shoushtari (244)
  6. Margaret Callahan (197)

More People

Years
  1. 2025 (22)
  2. 2024 (46)
  3. 2023 (66)
  4. 2022 (125)
  5. 2021 (112)
  6. 2020 (122)

More Years

Publications
  1. Journal of Clinical Oncology (330)
  2. Journal for ImmunoTherapy of Cancer (131)
  3. Cancer Research (106)
  4. Clinical Cancer Research (90)
  5. Annals of Oncology (77)
  6. Proceedings of the American Association for Cancer Research Annual Meeting (43)

More Publications

Publishers
  1. American Society of Clinical Oncology (342)
  2. American Association for Cancer Research (274)
  3. Biomed Central Ltd (148)
  4. Elsevier Inc. (144)
  5. Oxford University Press (109)
  6. Nature Publishing Group (88)

More Publishers

Results (1860)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts)
    Meeting Abstract

    McArthur, G. A.; Ribas, A.; Chapman, P. B.; Flaherty, K. T.; Kim, K. B.; Puzanov, I.; Nathanson, K. L.; Lee, R. J.; Koehler, A.; Spleiss, O.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy
    Meeting Abstract

    Lacouture, M. E.; Chapman, P. B.; Ribas, A.; Sosman, J. A.; McArthur, G. A.; Flaherty, K. T.; Kim, K. B.; Puzanov, I.; Nolop, K. B.; Joe, A. K.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM)
    Meeting Abstract

    Kim, K. B.; Flaherty, K. T.; Chapman, P. B.; Sosman, J. A.; Ribas, A.; McArthur, G. A.; Amaravadi, R. K.; Lee, R. J.; Nolop, K. B.; Puzanov, I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A pilot study of vaccination with sialyl Lewis(a) (sLe(a))-keyhole limpet hemocyanin (KLH) conjugate plus the immunologic adjuvant QS-21 in metastatic breast cancer patients (pts)
    Meeting Abstract

    Diab, A.; Ragupathi, G.; Scholz, W. W.; Panageas, K.; Hudis, C.; Livingston, P. O.; Gilewski, T.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis
    Meeting Abstract

    Callahan, M. K.; Yang, A.; Tandon, S.; Xu, Y.; Subudhi, S. K.; Roman, R. A.; Heine, A. I.; Pogoriler, E.; Kuk, D.; Panageas, K.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • An in-frame deletion in the N-terminal regulatory domain of BRAF(V600E) causes resistance to the RAF inhibitor PLX4032
    Meeting Abstract

    Poulikakos, P. I.; Persaud, Y.; Gabay, M. T.; Janakiraman, M.; Joseph, E. W.; Pratilas, C. A.; Chapman, P. B.; Rosen, N.; Solit, D. B.
    Cancer Research (2011)

    Fulltext@MSK | Save
  • Anti-tyrosinase related protein 1 (TRP1) antibody combined with cyclophosphamide induces adaptive immunity against melanoma
    Meeting Abstract

    Saenger, Y. M.; Pan, M.; Hashimoto, D.; Glodny, B.; Shah, S.; Houghton, A. N.; Merghoub, T.; Wolchok, J. D.; Merad, M.
    Cancer Research (2011)

    Fulltext@MSK | Save
  • Saponin QS-21 adjuvants in cancer vaccines
    Book Section

    Ragupathi, G.; Gardner, J. R.; Gin, D. Y.; Livingston, P. O.
    In Rappuoli, R.; DeGregorio, E. (Eds.) Novel Immunologic Adjuvants (2011)

    Fulltext@MSK | Save
  • Defining the critical hurdles in cancer immunotherapy
    Journal Article

    Fox, B. A.; Schendel, D. J.; Butterfield, L. H.; Aamdal, S.; Allison, J. P.; Ascierto, P. A.; Atkins, M. B.; Bartunkova, J.; Bergmann, L.; Berinstein, N.; more...
    Journal of Translational Medicine (2011)

    Fulltext@MSK | Save
  • Monocytic CCR2+myeloid derived suppressor cells promote immune escape by limiting activated CD8 T cell infiltration into the tumor microenvironment
    Meeting Abstract

    Lesokhin, A.; Hohl, T.; Merghoub, T.; Hirschhorn-Cymerman, D.; Pamer, E. G.; Houghton, A. N.; Wolchok, J. D.
    Blood (2011)

    Fulltext@MSK | Save